Martin Cannon, PhD

Martin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.

Martin Cannon, PhD, discusses data seen with immune checkpoint inhibitors in patients with ovarian cancer and why these agents are not as effective in this population as they are in other cancer types.

Martin Cannon, PhD, discusses explanations for the lack of success with immune checkpoint inhibitors in ovarian cancer, and how to potentially improve responses to immunotherapy approaches in this tumor type.

Martin Cannon, PhD, discusses the phase 1 investigation of the Th17 dendritic cell vaccine in ovarian cancer, and how it could potentially improve suboptimal responses when treated with immunotherapy alone in this population.